Valproate treatment and the risk of hyperandrogenism and polycystic ovaries

Bipolar Disorders

Volumn 2, Issue 1, 2000, Pages 37-41

  Soares, Jair C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Anticonvulsants; Bipolar disorder; Hyperandrogenism; Mood stabilizers; Polycystic ovaries; Side effects; Treatment; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; VALPROIC ACID;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; EPILEPSY; FEMALE; HUMAN; HYPERANDROGENISM; OVARY POLYCYSTIC DISEASE; RISK FACTOR; TIME;

ADULT; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TIME; VALPROIC ACID;

EID: 0034158415     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2000.020105.x     Document Type: Article

References (44)

1. Joffe RT. Valproate in bipolar disorder, the Canadian perspective. Can J Psychiatry 1993; 38 (3, Suppl 2): S46-S50.
2. McElroy SL, Keck PE, Jr. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 1993; 38 (3, Suppl 2): S62-S66.
3. Dubovsky SL, Buzan RD. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997; 58 (5): 224-242.
4. Dunn RT, Frye MS, Kimbrell TA, Denicoff KD, Leverich GS, Post RM. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol 1998; 21 (4): 215-235.
5. Bowden CL. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998; 19 (3): 194-199.
6. Keck PE, Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 (Suppl 6): 74-81.
7. Post RM, Frye MA, Denicoff KD, Leverich GS, Kimbrell TA, Dunn RT. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998; 19 (3): 206-219.
8. Post RM, Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, Speer A. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998; 38 (3): 152-166.
9. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980; 229 (1): 1-16.
10. Prasad AJ. The role of sodium valproate as an anti-manic agent. Pharmatherapeutica 1984; 4 (1): 6-8.
11. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8 (3): 243-250.
12. McElroy SL, Keck PE, Jr, Pope HG, Jr, Hudson JI. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 1988; 8 (4): 275-279.
13. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989; 50 (Suppl): 35-39.
14. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147 (4): 431-444.
15. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12 (Suppl 1): 53S-56S.
16. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56 (Suppl 3): 25-30.
17. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14 (5): 311-313.
18. Pope HG, Jr, McElroy SL, Keck PE, Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48 (1): 62-68.
19. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149 (1): 108-111.
20. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271 (12): 918-924.
21. Bowden CL, Swann AC, Calabrese JR, McElroy SL, Morris D, Petty F, Hirschfeld RM, Gyulai L. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997; 33 (4): 693-699.
22. Solomon DA, Keitner GI, Ryan CE, Miller IW. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J Clin Psychopharmacol 1998; 18 (1): 38-49.
23. Steffens DC, Krishnan KR. Decision model for the acute treatment of mania. Depress Anxiety 1996; 4 (6): 289-293.
24. Bowden CL, Davis J, Morris D, Swann A, Calabrese J, Lambert M, Goodnick P. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress Anxiety 1997; 6 (1): 26-30.
25. Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998; 59 (4): 172-174.
26. Fenn HH, Robinson D, Luby V, Dangel C, Buxton E, Beattie M, Kraemer H, Yesavage JA. Trends in pharmacotherapy of Schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996; 153 (5): 711-713.
27. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of mental health. Psychiatr Q 1998; 69 (4): 283-300.
28. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329 (19): 1383-1388.
29. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39 (5): 579-584.
30. Murialdo G, Galimberti CA, Magri F, Sampaolo P, Copello F, Gianelli MV, Gazzerro E, Rollero A, Deagatone C, Manni R, Ferrari E, Polleri A, Tartara A. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997; 20 (9): 519-526.
31. Murialdo G, Galimberti CA, Gianelli MV, Rollero A, Polleri A, Copello F, Magri F, Ferrari E, Sampaolo P, Manni R, Tartara A. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998; 21 (1): 52-58.
32. Isojarvi JI, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43 (4): 446-451.
33. Garland EJ, Behr R. Hormonal effects of valproic acid? J Am Acad Child Adolesc Psychiatry 1996; 35 (11): 1424-1425.
34. Irwin M, Masand P. Valproate and polycystic ovaries. J Am Acad Child Adolesc Psychiatry 1998; 37 (1): 9.
35. Geller B. Valproate and polycystic ovaries. J Am Acad Child Adolesc Psychiatry 1998; 37 (1): 9-10.
36. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic 1996; 39 (5): 559-560.
37. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341-346.
38. Bilo L, Meo R, Nappi C, Annunziato L, Striano S, Colao AM, Merola B, Buscaino GA. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988; 29: 612-619.
39. Herzog AG. Temporolimbic epilepsy and polycystic ovary syndrome. Fertil Steril 1996; 65: 210-211.
40. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 347-350.
41. Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Jpn J Psychiatry Neurol 1993; 47: 825-842.
42. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endoer Rev 1997; 18 (6): 774-800.
43. Goudas VT, Dumesic DA. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1997; 26 (4): 893-912.
44. Rosenfield RL. Current concepts of polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol 1997; 11 (2): 307-333.